Early diagnosis and treatment of gastric cancer using targeted imaging techniques
Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
This study is testing a new way to find and treat gastric cancer earlier by using special imaging techniques and a targeted antibody that focuses on a specific protein in tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06429891 on ClinicalTrials.gov |
What this trial studies
This project focuses on the early diagnosis of gastric cancer, which often presents with insidious symptoms leading to late-stage detection. It investigates the characteristics of the tumor microenvironment related to the MUC family of glycoproteins in solid tumors. Utilizing advanced techniques such as immunohistochemistry and gene sequencing, the study aims to develop a specific monoclonal antibody targeting MUC1, which could enhance the detection and treatment of gastric cancer. The approach includes innovative spatial analysis methods to better understand tumor biology and resistance mechanisms.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed solid tumors and measurable lesions.
Not a fit: Patients with significant hepatic or renal dysfunction, or those who are pregnant, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and more effective treatment options for patients with gastric cancer.
How similar studies have performed: While similar approaches have been explored, this specific methodology targeting the MUC family in gastric cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged ≥18 years old; ECOG 0 or 1; 2. Patients with solid tumor confirmed by histopathology; 3. Patients with imaging confirmed measurable lesions; 4. life expectancy \>=12 weeks. Exclusion Criteria: 1. Significant hepatic or renal dysfunction; 2. ls pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refusal to join the clinical study; 5. Suffering from claustrophobia or other mental diseases； 6. Any other situation that researchers think it is not suitable to participate in the experiment.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Hua Zhu — Peking University Cancer Hospital & Institute
- Study coordinator: Hua Zhu
- Email: zhuhuabch@pku.edu.cn
- Phone: +861088196495
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.